Clinical validation of immunoassay HemosIL® AcuStar HIT-IgG (PF4-H) in the diagnosis of Heparin-induced thrombocytopenia.


Journal

Journal of thrombosis and thrombolysis
ISSN: 1573-742X
Titre abrégé: J Thromb Thrombolysis
Pays: Netherlands
ID NLM: 9502018

Informations de publication

Date de publication:
Aug 2021
Historique:
accepted: 17 11 2020
pubmed: 3 1 2021
medline: 28 1 2022
entrez: 2 1 2021
Statut: ppublish

Résumé

Heparin induced thrombocytopenia (HIT) is a life and limb-threatening complication of heparin exposure. The misdiagnosis of this disease can have major consequences on the patients. The objective of this study was to evaluate a diagnostic strategy that combines the 4Ts score with the result of HemosIL® AcuStar HIT-IgG (PF4-H) to confirm the diagnosis of HIT. Citrated plasmas from 1300 patients with suspicion of HIT were analyzed with a fully automated quantitative chemiluminescent immunoassay (HemosIL® AcuStar HIT-IgG (PF4/H)). If the IgG anti-PF4/H antibodies were positive (cut-off, 1 U/mL), HIT diagnosis was confirmed using functional tests. In total, 1300 samples of consecutive patients were enrolled, 94 (7.2%) of which gave positive results in HemosIL® AcuStar-IgG. HIT was diagnosed in 65 out of these patients, corresponding to a prevalence of 5%. Using ROC curve analysis, patients were divided into three groups according to their titer of antibodies. Higher values of the IgG (PF4-H) were associated with increased probability of HIT, and the diagnostic specificity was greatly increased using the combination of a 4Ts score > 3 and a positive titer ≥ 3.25 U/mL. Importantly, the diagnostic specificity is 100% when the titer is > 12.40 U/mL. We demonstrated that higher values of Anti PF4/H Antibodies were associated with a high probability of having HIT. A titer of HemosIL® IgG (PF4-H) > 12.40 U/mL has a specificity of 100% which should no require a functional test to confirm the diagnosis of HIT.

Identifiants

pubmed: 33386560
doi: 10.1007/s11239-020-02349-4
pii: 10.1007/s11239-020-02349-4
doi:

Substances chimiques

Anticoagulants 0
Immunoglobulin G 0
Platelet Factor 4 37270-94-3
Heparin 9005-49-6

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

601-609

Informations de copyright

© 2021. Springer Science+Business Media, LLC, part of Springer Nature.

Références

Arepally GM (2017) Heparin-induced thrombocytopenia. Blood 129:2864–2872
doi: 10.1182/blood-2016-11-709873
Cuker A (2014) Clinical and laboratory diagnosis of heparin-induced thrombocytopenia: an integrated approach. Semin Thromb Hemost 40:106–114
pubmed: 24363239
Cuker A (2011) Heparin-induced thrombocytopenia: present and future. J Thromb Thrombolysis 31:353–366. https://doi.org/10.1007/s11239-011-0569-6
doi: 10.1007/s11239-011-0569-6 pubmed: 21327506
Cuker A, Arepally G, Crowther MA, Rice L, Datko F, Hook K et al (2010) The HIT expert probability (HEP) Score: a novel pre-test probability model for heparin-induced thrombocytopenia based on broad expert opinion. J Thromb Haemost 8:2642–2650
doi: 10.1111/j.1538-7836.2010.04059.x
Althaus K, Hron G, Strobel U, Abbate R, Rogolino A, Davidson S et al (2013) Evaluation of automated immunoassays in the diagnosis of heparin induced thrombocytopenia. Thromb Res 131:e85-90
doi: 10.1016/j.thromres.2013.01.005
Legnani C, Cini M, Pili C, Boggian O, Frascaro M, Palareti G (2010) Evaluation of a new automated panel of assays for the detection of anti-PF4/heparin antibodies in patients suspected of having heparin-induced thrombocytopenia. Thromb Haemost 104:402–409
doi: 10.1160/TH10-01-0002
Brodard J, Alberio L, Angelillo-Scherrer A, Nagler M (2020) Accuracy of heparin-induced platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia. Thromb Res 185:27–30
doi: 10.1016/j.thromres.2019.11.004
Chong BH, Burgess J, Ismail F (1993) The clinical usefulness of the platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia. Thromb Haemost 69:344–350
doi: 10.1055/s-0038-1651610
Marler J, Unzaga J, Stelts S, Oliphant CS (2015) Consequences of treating false positive heparin-induced thrombocytopenia. J Thromb Thrombolysis 40:512–514. https://doi.org/10.1007/s11239-015-1236-0
doi: 10.1007/s11239-015-1236-0 pubmed: 26036229
Cronin RE, Reilly RF (2010) Unfractionated heparin for hemodialysis: still the best option. Semin Dial 23:510–515
doi: 10.1111/j.1525-139X.2010.00770.x
Zheng G, Streiff MB, Allison D, Takemoto CM, Salimian K, Morris P et al (2018) A novel diagnostic algorithm for heparin-induced thrombocytopenia. Int J Lab Hematol. https://doi.org/10.1111/ijlh.12853
doi: 10.1111/ijlh.12853 pubmed: 30264491
Zwicker JI, Uhl L, Huang W-Y, Shaz BH, Bauer KA (2004) Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia. J Thromb Haemost 2:2133–2137
doi: 10.1111/j.1538-7836.2004.01039.x
Warkentin TE, Sheppard JI, Moore JC, Sigouin CS, Kelton JG (2008) Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays. J Thromb Haemost 6:1304–1312
doi: 10.1111/j.1538-7836.2008.03025.x
Cuker A, Gimotty PA, Crowther MA, Warkentin TE (2012) Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis. Blood 120:4160–4167
doi: 10.1182/blood-2012-07-443051
Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A (2006a) Evaluation of pretest clinical score (4 T’s) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 4:759–65
doi: 10.1111/j.1538-7836.2006.01787.x
Thomas T, Fuentes A, Xu Q, Donahue K (2019) Evaluation of heparin induced thrombocytopenia using probability scores in a mechanical circulatory support population. J Thromb Thrombolysis 48:134–140
doi: 10.1007/s11239-019-01843-8
Minet V, Dogné J-M, Mullier F (2017) Functional assays in the diagnosis of heparin-induced thrombocytopenia. Molecules 22:617
doi: 10.3390/molecules22040617
Prechel M, Walenga JM (2012) Heparin-induced thrombocytopenia: an update. Semin Thromb Hemost 38:483–496
doi: 10.1055/s-0032-1306432
Sheridan D, Carter C, Kelton JG (1986) A diagnostic test for heparin-induced thrombocytopenia. Blood 67:27–30
doi: 10.1182/blood.V67.1.27.27
Vayne C, Guery E-A, Kizlik-Masson C, Rollin J, Bauters A, Gruel Y et al (2017) Beneficial effect of exogenous platelet factor 4 for detecting pathogenic heparin-induced thrombocytopenia antibodies. Br J Haematol 179:811–819
doi: 10.1111/bjh.14955
Warkentin TE, Sheppard J-AI, Linkins L-A, Arnold DM, Nazy I (2018) High sensitivity and specificity of an automated IgG-specific chemiluminescence immunoassay for diagnosis of HIT. Blood 132:1345–1349
doi: 10.1182/blood-2018-04-847483
Bakchoul T, Giptner A, Najaoui A, Bein G, Santoso S, Sachs UJH (2009) Prospective evaluation of PF4/heparin immunoassays for the diagnosis of heparin-induced thrombocytopenia. J Thromb Haemost 7:1260–1265
doi: 10.1111/j.1538-7836.2009.03465.x
Juhl D, Eichler P, Lubenow N, Strobel U, Wessel A, Greinacher A (2006) Incidence and clinical significance of anti-PF4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparin-induced thrombocytopenia. Eur J Haematol 76:420–426
doi: 10.1111/j.1600-0609.2005.00621.x
Pierce W, Mazur J, Greenberg C, Mueller J, Foster J, Lazarchick J (2013) Evaluation of heparin-induced thrombocytopenia (HIT) laboratory testing and the 4Ts scoring system in the intensive care unit. Ann Clin Lab Sci 43:429–435
pubmed: 24247801
Chong BH, Chong JJH (2004) Heparin-induced thrombocytopenia. Expert Rev Cardiovasc Ther 2:547–559
doi: 10.1586/14779072.2.4.547
Warkentin TE, Arnold DM, Nazi I, Kelton JG (2015) The platelet serotonin-release assay. Am J Hematol 90:564–572
doi: 10.1002/ajh.24006
Martel N, Lee J, Wells PS (2005) Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood 106:2710–2715
doi: 10.1182/blood-2005-04-1546
Arepally GM, Ortel TL (2010) Heparin-induced thrombocytopenia. Annu Rev Med 61:77–90
doi: 10.1146/annurev.med.042808.171814
Warkentin TE, Sheppard JA, Horsewood P, Simpson PJ, Moore JC, Kelton JG (2000) Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 96:1703–1708
doi: 10.1182/blood.V96.5.1703
Pishko AM, Cuker A (2017) Heparin-induced thrombocytopenia in cardiac surgery patients. Semin Thromb Hemost 43:691–698
doi: 10.1055/s-0037-1602664
Pouplard C, May MA, Iochmann S, Amiral J, Vissac AM, Marchand M et al (1999) Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin: clinical implications for heparin-induced thrombocytopenia. Circulation 99:2530–2536
doi: 10.1161/01.CIR.99.19.2530
Pearson M-A, Nadeau C, Blais N (2014) Correlation of ELISA optical density with clinical diagnosis of heparin-induced thrombocytopenia: a retrospective study of 104 patients with positive anti-PF4/heparin ELISA. Clin Appl Thromb 20:349–354
doi: 10.1177/1076029613513319
Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A (2006b) Evaluation of pretest clinical score (4 T’s) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 4:759–765
doi: 10.1111/j.1538-7836.2006.01787.x
Lillo-Le Louët A, Boutouyrie P, Alhenc-Gelas M, Le Beller C, Gautier I, Aiach M et al (2004) Diagnostic score for heparin-induced thrombocytopenia after cardiopulmonary bypass. J Thromb Haemost 2:1882–1888
doi: 10.1111/j.1538-7836.2004.00949.x
Crowther MA, Cook DJ, Albert M, Williamson D, Meade M, Granton J et al (2010) The 4Ts scoring system for heparin-induced thrombocytopenia in medical-surgical intensive care unit patients. J Crit Care 25:287–293
doi: 10.1016/j.jcrc.2009.12.006
Linkins L-A, Bates SM, Lee AYY, Heddle NM, Wang G, Warkentin TE (2015) Combination of 4Ts score and PF4/H-PaGIA for diagnosis and management of heparin-induced thrombocytopenia: prospective cohort study. Blood 2015(126):597–603
doi: 10.1182/blood-2014-12-618165
Nellen V, Sulzer I, Barizzi G, Lämmle B, Alberio L (2012) Rapid exclusion or confirmation of heparin-induced thrombocytopenia: a single-center experience with 1,291 patients. Haematologica 97:89–97
doi: 10.3324/haematol.2011.048074
Favaloro EJ (2015) Toward improved diagnosis of HIT. Blood 126:563–564
doi: 10.1182/blood-2015-05-644740
Pishko AM, Fardin S, Lefler DS, Paydary K, Vega R, Arepally GM et al (2018) Prospective comparison of the HEP score and 4Ts score for the diagnosis of heparin-induced thrombocytopenia. Blood Adv 2(22):3155–62
doi: 10.1182/bloodadvances.2018023077

Auteurs

Zeina Marashi-Sabouni (Z)

Laboratoire d'Hématologie, La Timone Hospital, APHM, Boulevard Jean- Moulin, 13005, Marseille, France.

Caroline Vayne (C)

Service d'Hématologie Hémostase, Hôpital Trousseau, CHU de Tours, 37044, Tours, France.
EA7501 GICC, Université de Tours, Tours, France.

Manal Ibrahim-Kosta (M)

Laboratoire d'Hématologie, La Timone Hospital, APHM, Boulevard Jean- Moulin, 13005, Marseille, France.
Aix Marseille Univ, INSERM, INRAE, C2VN, Marseille, France.

Catherine Guidon (C)

Department of Anaesthesiology and Critical Care Medicine, University Hospital Timone, Marseille, France.

Anderson Loundou (A)

Biostatistic and Public Health Department, La Timone Hospital, Marseille, France.

Eve Anne Guery (EA)

Service d'Hématologie Hémostase, Hôpital Trousseau, CHU de Tours, 37044, Tours, France.

Pierre-Emmanuel Morange (PE)

Laboratoire d'Hématologie, La Timone Hospital, APHM, Boulevard Jean- Moulin, 13005, Marseille, France.
Aix Marseille Univ, INSERM, INRAE, C2VN, Marseille, France.

Laurence Camoin-Jau (L)

Laboratoire d'Hématologie, La Timone Hospital, APHM, Boulevard Jean- Moulin, 13005, Marseille, France. laurence.camoin@ap-hm.fr.
Aix Marseille Univ, IRD, APHM, MEPHI, IHU Méditerranée Infection, Marseille, France. laurence.camoin@ap-hm.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH